Tweet
I have just loaded the latest CummeRbund program v2.01 and have a few questions. My RNAseq data is from 3 time points where each timepoint has a control C1, C2, C3 and an experimental condition E1 , E2 and E3. I have created cuffdiff output for all pairwise comparisons C1_E1, C2_E2, C3_E3. Should I save all cuffdiff output into a single directory for creating plots for all conditions? Also how do you save plots that are generated with CummeRbund?
-
-
Did you run cuffdiff 3 times for each paired comparison? Then you'll loose the biological replicate variance and have to rely on cuffdiff's guessed variance. But seeing as the samples are paired, I don't really know how you would do it otherwise. I'm actually wondering this since I have paired data but don't know how to keep the paired information when running cuffdiff. For example: Family1_sampleA, Family1_sampleB, Family2_sampleA, Family2_sampleB, etc.Originally posted by godzilla07 View Post
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...Today, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment